ErSO

Research use only, not for human use.

ErSO is a selective activator of anticipatory unfolded protein response (UPR) via ERα receptor. ErSO can be used in studies about anti-cancer.

ErSO is a selective activator of anticipatory unfolded protein response (UPR) via ERα receptor. ErSO can be used in studies about anti-cancer.(In Vitro):In MCF-7 cells, ErSO (1-1000 nM) inhibits cell viability with an IC50 of 20.3 nM. ErSO (1 μM) rapidly kills ERα-positive breast cancer cells in TYS and TDG cells and induces rapid killing of ERα-positive MCF-7 human breast cancer cells.(In Vivo):ErSO (10 and 40 mg/kg; p.o.) induces >100000-fold regression (to undetectable amounts) within 14 days and >10000-fold regression of TYS-luciferase-expressing breast tumors in all five mice. In Nu/J mice, ErSO (10 or 40 mg/kg; p.o.) eliminates tumors with >90% reduction in all cases.

Cell Viability Assay Cell Line:MCF-7 cells Concentration:1~1000 nM Incubation Time:24 hours Result: Showed that IC50 value is 20.3 nM in MCF-7 cells and inhibited cell viability.

Animal Model:Nu/J mice Dosage:10 or 40 mg/kg Administration:P.o.; 21 days Result:Resulted in elimination of these tumors, with >90% reduction in all cases.Animal Model:Mice Dosage:0.5~40 mg/kg Administration:P.o.; 3 weeks Result:Sufficient for a robust response.Animal Model:Mice Dosage:40 mg/kg Administration:I.p.; 14 days Result:Metastatic burden was greatly reduced

——

Others

Other Targets

γ secretase

——

——

2407860-35-7

453.33

C22H13F6NO3

>98% (HPLC)

In Vitro:?DMSO : 120 mg/mL (264.71 mM)

O=C1[C@@](C=2C(N1)=C(C(F)(F)F)C=CC2)(C3=CC=C(OC(F)(F)F)C=C3)C4=CC=C(O)C=C4

——

(-20℃)

With Ice Pack

≥ 2 years